Kondrat'eva N A, Gershanovich M L, Kondrat'ev V B, Lebedev V N, Vialushkin V Ia
Vopr Onkol. 1981;27(4):82-7.
A coordinated clinical trial (phase II) of preparation VM-26 supplied by Sandos (Switzerland) was carried out at 5 clinics in a total of 61 patients with lymphoma. Two regimens of VM-26 administration were employed: (1) 5-day courses of 30 mg/m2 iv with 7-14 day intervals, or (2) two injections of 50 mg/m2 a week, within 4-6 weeks, depending on drug tolerance Out of 15 children with Hodgkin's disease, 50% of cases showed complete or partial remission. Out of 27 adults with Hodgkin's disease, response was registered in 69.9 and a pronounced effect--in 1 26.1%. Out of 14 patients with lymphosarcomas, response was observed in 78.5 and a pronounced effect--in 57.2%. Toxic effect was not the cause of treatment suspension in most cases.
由瑞士山德士公司提供的VM - 26制剂进行了一项协调性临床试验(II期),在5家诊所对总共61例淋巴瘤患者开展。采用了两种VM - 26给药方案:(1)每平方米体表面积静脉注射30毫克,为期5天疗程,间隔7 - 14天;或(2)根据药物耐受性,在4 - 6周内每周注射两次,每次每平方米体表面积50毫克。在15例霍奇金病患儿中,50%的病例出现完全或部分缓解。在27例成人霍奇金病患者中,69.9%有反应,其中26.1%有显著效果。在14例淋巴肉瘤患者中,78.5%有反应,其中57.2%有显著效果。在大多数情况下,毒性作用并非导致治疗中断的原因。